BRIEF-Merck Announces Phase 3 KEYLYNK-001 Trial Met Primary Endpoint in Patients With Ovarian Cancer

Reuters
09 Dec 2024

Dec 9 (Reuters) - Merck & Co Inc :

* MERCK ANNOUNCES PHASE 3 KEYLYNK-001 TRIAL MET PRIMARY ENDPOINT OF PROGRESSION-FREE SURVIVAL $(PFS)$ IN PATIENTS WITH ADVANCED EPITHELIAL OVARIAN CANCER

* MERCK & CO INC - STUDY DID NOT REACH SECONDARY ENDPOINT OF OVERALL SURVIVAL

* MERCK & CO INC - SAFETY PROFILES OF KEYTRUDA AND LYNPARZA CONSISTENT WITH PREVIOUS STUDIES

Source text: Further company coverage:

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10